Rationale of Using Common Antifibrotic Therapy in Post COVID Fibrosis. Journal of Medicine, [S. l.], v. 22, n. 1, p. 46–50, 2021. DOI: 10.3329/jom.v22i1.51391. Disponível em: https://www.banglajol.info/index.php/JOM/article/view/51391. Acesso em: 27 jun. 2026.